Article
Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage.
FEBS open bio - 1 Mar 2021
Hong Yuan, Feng Yingcai, Sun Hanzi, Zhang Bo, Wu Hongfu, Zhu Qing, Li Yucheng, Zhang Tong, Zhang Yilu, Cui Xinxin, Li Zhuo, Song Xiaomin, Li Kang, Liu Mike, Liu Ye
Abstract excerpt
Programmed cell death protein 1 (PD-1), an immune checkpoint receptor expressed by activated T, B, and NK cells, is a well-known target for cancer immunotherapy. Tislelizumab (BGB-A317) is an anti-PD-1 antibody that has recently been approved for treatment of Hodgkin's lymphoma and urothelial carcinoma. Here, we show that tislelizumab displayed remarkable antitumor efficacy in a B16F10/GM-CSF mouse model....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.